Table 2.
Relative potency and maximal effects of several nucleotide agonists on vasodilation and NO release in human placental cotyledon
| Dilatation | NO release | |||
|---|---|---|---|---|
| EC50 (nm) | Emax (%) | EC50 (nm) | Emax (pmol) | |
| 2-MeSATP | 4.2 ± 0.7 | 68 ± 13 (4) | 83 ± 8 | 353 ± 51 (5) |
| 2-MeSADP | 7.2 ± 0.6 | 75 ± 9 (5) | 27 ± 4 | 201 ± 33 (4) |
| UTP | 86 ± 7 | 56 ± 7 (5) | 1843 ± 124 | 120 ± 17 (4) |
| UDP | >10 000 | 12 ± 7 (4) | ≫10 000 | 14 ± 5 (4) |
| ATP | 322 ± 21 | 57 ± 8 (5) | ≫10 000 | <5 (4) |
Values in parenthesis indicate the number of experiments performed.